TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000302125
  • Gene Name:MZB1
  • mRNA database:Ensembl
  • mRNA expression :down-regulated
  • mRNA Method:PCR
  • mRNA Pathway:NA
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB13172
  • Drug Name:Tunicamycin
  • Drug Method:down-regulated the gene expression

Disease basic infommation

  • Disease:systemic lupus erythematosus
  • Tissue:patients tissues

Other information

  • Title:Increase of MZB1 in B cells in systemic lupus erythematosus: proteomic analysis of biopsied lymph nodes
  • Journal:Arthritis Research & Therapy
  • Published:2018
  • PubMed ID:29382365
  • Abstract:Background:Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease in which dysregulation of B cells has been recognized. Here, we searched for potential biomarkers of SLE using liquid chromatography-tandem mass spectrometry (LC-MS). Methods:Lymph nodes from SLE patients and controls were analyzed by LC-MS. To validate the identified molecules, immunoblotting and immunohistochemistry were performed and B cells from SLE patients were analyzed by quantitative RT-PCR. B-cell subsets from NZB/W F1 mice, which exhibit autoimmune disease resembling human SLE, were analyzed by flow cytometry. Endoplasmic reticulum (ER) stress was induced by tunicamycin and the serum concentration of anti-dsDNA antibodies was determined by ELISA. TUNEL methods and immunoblotting were used to assess the effect of tunicamycin. Results:MZB1, which comprises part of a B-cell-specific ER chaperone complex and is a key player in antibody secretion, was one of the differentially expressed proteins identified by LC-MS and confirmed by immunoblotting. Immunohistochemically, larger numbers of MZB1+cells were located mainly in interfollicular areas and scattered in germinal centers in specimens from SLE patients compared with those from controls. MZB1 colocalized with CD138+plasma cells and IRTA1+marginal zone B cells. MZB1 mRNA was increased by 2.1-fold in B cells of SLE patients with active disease (SLE Disease Activity Index 2000 ≥ 6) compared with controls. In aged NZB/W F1 mice, splenic marginal zone B cells and plasma cells showed elevated MZB1 levels. Tunicamycin induced apoptosis of MZB1+cells in target organs, resulting in decreased serum anti-dsDNA antibody levels. Additionally, MZB1+cells were increased in synovial tissue specimens from patients with rheumatoid arthritis. Conclusions:MZB1 may be a potential therapeutic target in excessive antibody-secreting cells in SLE.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3